The role of health economic evidence in the development of clinical practice guidelines_Chinese Journal of Evidence-Based Medicine

Authors：

GUO Wenhao ^1,2 , LI Yan ^1,2 , WANG Siyue ^1,2 , HU Bingqi ^1,2 ,  LI Hongchao ^1,2

1. School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, P. R. China;
2. Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing 211198, P. R. China;

Corresponding?author：

LI Hongchao, Email: lihongchao@cpu.edu.cn

Keywords：

Health economic evidence; Clinical practice guideline; Health economic evaluation

DOI：

10.7507/1672-2531.202305121

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

This article aims to explore the application of health economics evidence in the development of clinical practice guidelines and evidence recommendations, and to provide better references for clinical decision-making. By reviewing the use of health economics evidence in domestic and international clinical practice guidelines, the difficulties in the application of health economics evidence in the development of clinical practice guidelines and evidence recommendations were summarized. It was found that there were significant differences in the use of health economics evidence in clinical practice guidelines in different countries, and these differences were affected by the goals of clinical practice guidelines and limitations of health economics evidence itself, lacking standardized methodological guidance, resulting in limited use of health economics evidence in clinical practice guidelines. Therefore, further research is needed to optimize the integration of health economics and clinical practice guidelines, and develop standardized methodological guidance.

Citation： GUO Wenhao, LI Yan, WANG Siyue, HU Bingqi, LI Hongchao. The role of health economic evidence in the development of clinical practice guidelines. Chinese Journal of Evidence-Based Medicine, 2024, 24(1): 91-97. doi: 10.7507/1672-2531.202305121 Copy

1.	NIH. About systematic evidence reviews and clinical practice guidelines.
2.	Institute Of Medicine (US) Committee On Clinical Practice Guidelines. Guidelines for clinical practice: from development to use. Washington DC: National Academies Press (US), 1992.
3.	Williams A. How should information of cost-effectiveness influence practice. London: BMJ, 1995.
4.	桂裕亮, 韓晟, 曾憲濤, 等. 衛生經濟學評價研究方法學質量評價工具簡介. 河南大學學報(醫學版), 2017, 36(2): 129-132.
5.	楊欽博, 周奇, 黃天相, 等. 2017年中國大陸期刊發表的臨床實踐指南的報告質量評價. 中國循證醫學雜志, 2019, 19(11): 1325-1332.
6.	Ramsey SD. Economic analyses and clinical practice guidelines: why not a match made in heaven. J Gen Intern Med, 2002, 17(3): 235-237.
7.	Sharlip ID, Belker AM, Honig S, et al. Vasectomy: AUA guideline. J Urol, 2012, 188(6 Suppl): 2482-2491.
8.	Schwartz JA, Pearson SD. Cost consideration in the clinical guidance documents of physician specialty societies in the United States. JAMA Intern Med, 2013, 173(12): 1091-1097.
9.	Task Force on the Low Back Pain Clinical Practice Guidelines. American Osteopathic Association guidelines for osteopathic manipulative treatment (OMT) for patients with low back pain. J Am Osteopath Assoc, 2016, 116(8): 536-549.
10.	桂裕亮, 楊亮, 曾憲濤, 等. 臨床實踐指南制訂方法—經濟學證據在指南制訂中的應用. 中國循證心血管醫學雜志, 2018, 10(11): 1285-1288.
11.	NICE. Safeguarding adults in care homes. 2021.
12.	Eldis. Private sector involvement in funding and providing health services in South Africa: implications for equity and access to health care.
13.	Wilkinson M, Hofman KJ, Young T, et al. Health economic evidence in clinical guidelines in South Africa: a mixed-methods study. BMC Health Serv Res, 2021, 21(1): 738.
14.	王彥博, 王強, 趙明娟, 等. 2018年中國發布臨床實踐指南利益沖突與經濟學證據的調查分析. 醫學新知, 2020, 30(2): 139-158.
15.	王強, 黃超, 李俊, 等. 2017年中國發布的臨床實踐指南中利益沖突與經濟學證據的調查分析. 中國循證醫學雜志, 2018, 18(4): 379-387.
16.	葉進, 喻閩鳳, 徐卉卉, 等. 中醫兒科臨床診療指南蛔蟲病(修訂). 中醫兒科雜志, 2017, 13(6): 6-10.
17.	陳耀龍, 楊克虎, 王小欽, 等. 中國制訂/修訂臨床診療指南的指導原則(2022版). 中華醫學雜志, 2022, 102(10): 697-703.
18.	Sanabria AJ, Kotzeva A, Selva Olid A, et al. Most guideline organizations lack explicit guidance in how to incorporate cost considerations. J Clin Epidemiol, 2019, 116: 72-83.
19.	劉國思. 中國藥物經濟學評價指南2020: 中英雙語版. 北京: 中國市場出版社, 2020.
20.	Guyatt GH, Oxman AD, Montori V, 等. GRADE指南: Ⅴ. 證據質量評價—發表偏倚. 中國循證醫學雜志, 2011, 11(12): 1430-1434.
21.	Cheng J, Zhang Y, Zhong A, et al. Quality of health economic evaluations in mainland China: a comparison of peer-reviewed articles in Chinese and in English. Appl Health Econ Health Policy, 2022, 20(1): 35-54.
22.	Kaplan RM. Health status and health policy: quality of life in health care evaluation and resource allocation. Qual Life Res, 1994, 3(6): 457-458.
23.	van Mastrigt GA, Hiligsmann M, Arts JJ, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res, 2016, 16(6): 689-704.
24.	Mathes T, Walgenbach M, Antoine SL, et al. Methods for systematic reviews of health economic evaluations: a systematic review, comparison, and synthesis of method literature. Med Decis Making, 2014, 34(7): 826-840.
25.	Schünemann H, Hill S, Guyatt G, et al. The GRADE approach and Bradford Hill's criteria for causation. J Epidemiol Community Health, 2011, 65(5): 392-395.
26.	National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. 2015.
27.	Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics, 2004, 22(13): 857-876.
28.	World Health Organization. WHO handbook for guideline development (2nd Edition).
29.	Brouwers MC, Kho ME, Browman GP, et al. AGREE Ⅱ: advancing guideline development, reporting, and evaluation in health care. Prev Med, 2010, 51(5): 421-424.
30.	靳英輝, 張林, 黃笛, 等. 臨床實踐指南制定方法—指南制定參與人員及組成分配. 中國循證心血管醫學雜志, 2018, 10(4): 385-391.
31.	National Institute for Health and Care Excellence. The guidelines manual. London: National Institute for Health and Care Excellence (NICE), 2012.
32.	Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health, 2013, 16(2): 231-250.
33.	Husereau D, Drummond M, Augustovski F, 等. 衛生經濟學評價報告標準共識2022 (CHEERS 2022): 衛生經濟學評價報告指導意見更新版. 英國醫學雜志中文版, 2022, 25(8): 460-465.
34.	Critical Appraisal Skills Programme. CASP checklists - critical appraisal skills programme.
35.	National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [Internet]. London: National Institute for Health and Care Excellence (NICE), 2022.

1. NIH. About systematic evidence reviews and clinical practice guidelines.
2. Institute Of Medicine (US) Committee On Clinical Practice Guidelines. Guidelines for clinical practice: from development to use. Washington DC: National Academies Press (US), 1992.
3. Williams A. How should information of cost-effectiveness influence practice. London: BMJ, 1995.
4. 桂裕亮, 韓晟, 曾憲濤, 等. 衛生經濟學評價研究方法學質量評價工具簡介. 河南大學學報(醫學版), 2017, 36(2): 129-132.
5. 楊欽博, 周奇, 黃天相, 等. 2017年中國大陸期刊發表的臨床實踐指南的報告質量評價. 中國循證醫學雜志, 2019, 19(11): 1325-1332.
6. Ramsey SD. Economic analyses and clinical practice guidelines: why not a match made in heaven. J Gen Intern Med, 2002, 17(3): 235-237.
7. Sharlip ID, Belker AM, Honig S, et al. Vasectomy: AUA guideline. J Urol, 2012, 188(6 Suppl): 2482-2491.
8. Schwartz JA, Pearson SD. Cost consideration in the clinical guidance documents of physician specialty societies in the United States. JAMA Intern Med, 2013, 173(12): 1091-1097.
9. Task Force on the Low Back Pain Clinical Practice Guidelines. American Osteopathic Association guidelines for osteopathic manipulative treatment (OMT) for patients with low back pain. J Am Osteopath Assoc, 2016, 116(8): 536-549.
10. 桂裕亮, 楊亮, 曾憲濤, 等. 臨床實踐指南制訂方法—經濟學證據在指南制訂中的應用. 中國循證心血管醫學雜志, 2018, 10(11): 1285-1288.
11. NICE. Safeguarding adults in care homes. 2021.
12. Eldis. Private sector involvement in funding and providing health services in South Africa: implications for equity and access to health care.
13. Wilkinson M, Hofman KJ, Young T, et al. Health economic evidence in clinical guidelines in South Africa: a mixed-methods study. BMC Health Serv Res, 2021, 21(1): 738.
14. 王彥博, 王強, 趙明娟, 等. 2018年中國發布臨床實踐指南利益沖突與經濟學證據的調查分析. 醫學新知, 2020, 30(2): 139-158.
15. 王強, 黃超, 李俊, 等. 2017年中國發布的臨床實踐指南中利益沖突與經濟學證據的調查分析. 中國循證醫學雜志, 2018, 18(4): 379-387.
16. 葉進, 喻閩鳳, 徐卉卉, 等. 中醫兒科臨床診療指南蛔蟲病(修訂). 中醫兒科雜志, 2017, 13(6): 6-10.
17. 陳耀龍, 楊克虎, 王小欽, 等. 中國制訂/修訂臨床診療指南的指導原則(2022版). 中華醫學雜志, 2022, 102(10): 697-703.
18. Sanabria AJ, Kotzeva A, Selva Olid A, et al. Most guideline organizations lack explicit guidance in how to incorporate cost considerations. J Clin Epidemiol, 2019, 116: 72-83.
19. 劉國思. 中國藥物經濟學評價指南2020: 中英雙語版. 北京: 中國市場出版社, 2020.
20. Guyatt GH, Oxman AD, Montori V, 等. GRADE指南: Ⅴ. 證據質量評價—發表偏倚. 中國循證醫學雜志, 2011, 11(12): 1430-1434.
21. Cheng J, Zhang Y, Zhong A, et al. Quality of health economic evaluations in mainland China: a comparison of peer-reviewed articles in Chinese and in English. Appl Health Econ Health Policy, 2022, 20(1): 35-54.
22. Kaplan RM. Health status and health policy: quality of life in health care evaluation and resource allocation. Qual Life Res, 1994, 3(6): 457-458.
23. van Mastrigt GA, Hiligsmann M, Arts JJ, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res, 2016, 16(6): 689-704.
24. Mathes T, Walgenbach M, Antoine SL, et al. Methods for systematic reviews of health economic evaluations: a systematic review, comparison, and synthesis of method literature. Med Decis Making, 2014, 34(7): 826-840.
25. Schünemann H, Hill S, Guyatt G, et al. The GRADE approach and Bradford Hill's criteria for causation. J Epidemiol Community Health, 2011, 65(5): 392-395.
26. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. 2015.
27. Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics, 2004, 22(13): 857-876.
28. World Health Organization. WHO handbook for guideline development (2nd Edition).
29. Brouwers MC, Kho ME, Browman GP, et al. AGREE Ⅱ: advancing guideline development, reporting, and evaluation in health care. Prev Med, 2010, 51(5): 421-424.
30. 靳英輝, 張林, 黃笛, 等. 臨床實踐指南制定方法—指南制定參與人員及組成分配. 中國循證心血管醫學雜志, 2018, 10(4): 385-391.
31. National Institute for Health and Care Excellence. The guidelines manual. London: National Institute for Health and Care Excellence (NICE), 2012.
32. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health, 2013, 16(2): 231-250.
33. Husereau D, Drummond M, Augustovski F, 等. 衛生經濟學評價報告標準共識2022 (CHEERS 2022): 衛生經濟學評價報告指導意見更新版. 英國醫學雜志中文版, 2022, 25(8): 460-465.
34. Critical Appraisal Skills Programme. CASP checklists - critical appraisal skills programme.
35. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [Internet]. London: National Institute for Health and Care Excellence (NICE), 2022.

Chinese Journal of Evidence-Based Medicine

The role of health economic evidence in the development of clinical practice guidelines

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content